参附注射液联合DP方案治疗晚期非小细胞肺癌临床观察  

Clinical study of Shenfu injection combined with DP regimen in treatment of advanced non-small cell lung cancer

作　　者：柏茂树[1] 王熙才[2] 梁百武 

机构地区：[1]达州市中西医结合医院肿瘤科,四川达州635000 [2]昆明医科大学第三附属医院肿瘤研究所,云南昆明650118

出　　处：《现代肿瘤医学》2014年第1期56-58,共3页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81060177)

摘　　要：目的:评价参附注射液对DP方案治疗非小细胞肺癌的减毒增效作用。方法:78例晚期非小细胞肺癌患者随机分为治疗组(39例)和对照组(39例)。治疗组采用参附注射液联合DP方案化疗,对照组单用DP方案化疗。21天为1个周期,2周期后评价疗效。结果:治疗组有效率(CR+PR)51.3%,对照组38.5%,两组比较无统计学差异(P>0.05);治疗组临床受益率(CBR)82.1%,对照组66.7%,两组比较有统计学差异(P<0.05)。主要不良反应为骨髓抑制和胃肠道反应,治疗组Ⅲ/Ⅳ度白细胞减少及血红蛋白减少低于对照组,两组比较差异有统计学意义。结论:参附注射液联合DP方案对晚期非小细胞肺癌可增加临床疗效,减轻不良反应,值得临床推广应用。Objective：To investigate the toxicity-reducing and synergistic effects of Shenfu injection for DP regimen in patients with advanced non-small cell lung cancer （NSCLC）.Methods：Seventy-eight patients were divided into treatment group （n=39） and control group （n=39） randomly.Patients in control group were treated with docetaxel and cisplatin.Patients in treatment group were given docetaxel,cisplatin and Shenfu injection.21 days for one cycle,after two cycles were evaluated.Results：The efficacy （CR＋PR） was 51.3% in treatment group and 38.5% in control group,and there was no significant difference between the two groups （P〉0.05）.Clinical benefit rate（CBR）：treatment group 82.1%,control group 66.7% （P〈0.05）.The major adverse effects included leukopenia,anemia and gastrointestinal reactions.The leukopenia of III / IV degree and anemia in treatment group was lower than control group （P〈0.05）.Conclusion：Shenfu injection combined with DP regimen could increase the therapeutic effects and decrease the side effects of chemotherapy in the patients with advanced non-small cell lung cancer.

关 键 词：参附注射液 非小细胞肺癌 DP方案 化疗 减毒增效 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]